Skip to content
Trial Agents

Onkologicky Ustav Sv Alzbety s.r.o

Onkologicky Ustav Sv Alzbety s.r.o is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.

2distinct trials
2recorded service labels
0trials with learnings

Data snapshot: 2026-10-09 · About the data

Clinical trial experience

Showing 2 of 2 trials · Latest update first

PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer

Sponsor Novartis Pharma AG

Start (EU)
Latest update
Estimated end

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)

Sponsor Novartis Pharma AG

Start (EU)
Latest update
Estimated end

Questions about this trial experience

What services are recorded for Onkologicky Ustav Sv Alzbety s.r.o?

The 2026-10-09 snapshot links Onkologicky Ustav Sv Alzbety s.r.o to 2 distinct CTIS trials. Recorded services include 177Lu-PSMA-617 administration, Lutecium administration. These are study-specific roles, not a complete or independently verified capability catalogue.

Which therapeutic areas and study phases are recorded for Onkologicky Ustav Sv Alzbety s.r.o?

The most frequently recorded therapeutic areas are Solid Tumor Oncology, Urology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.

In which countries are trials linked to Onkologicky Ustav Sv Alzbety s.r.o conducted?

The linked trials record locations in 12 countries, including Austria, Belgium, Czechia, Germany, Spain. These are trial locations, not confirmed office locations or countries where Onkologicky Ustav Sv Alzbety s.r.o delivered services.

What can this page tell me about Onkologicky Ustav Sv Alzbety s.r.o's trial experience?

Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.

About this data & company names

One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.

Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.

Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Onkologicky Ustav Sv Alzbety s.r.o. Legacy brands remain separate unless explicitly matched in the name registry.

View recorded company names
  • Onkologicky Ustav Sv Alzbety s.r.o.

Never miss a new clinical trial insight

We continuously analyze new and updated clinical trial data and publish practical, evidence-led reports for clinical leaders.